Bicara Therapeutics Inc., a biopharmaceutical firm in the clinical development phase, is headquartered in Boston, Massachusetts. Established in 2018, the company specializes in creating innovative, dual-action treatments specifically for solid tumors. At the forefront of their pipeline is ficerafusp alfa, a unique antibody designed to tackle solid cancers. This bifunctional therapeutic agent works by simultaneously engaging the epidermal growth factor receptor (EGFR) and binding to human transforming growth factor beta (TGF-b). Bicara Therapeutics operates as a subsidiary of Biocon Limited.
| Metric | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|
| Revenue | N/A | N/A | N/A |
| Cost of Revenue | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A |
| Gross Margin | 0.00% | 0.00% | 0.00% |
| Operating Expenses | $82.39M | $39.89M | $37.66M |
| Operating Income | $-82.39M | $-39.89M | $-37.66M |
| Operating Margin | 0.00% | 0.00% | 0.00% |
| Net Income | $-68.00M | $-51.98M | $-37.84M |
| Net Margin | 0.00% | 0.00% | 0.00% |
| EPS (Basic) | $-1.25 | $-1.00 | $-0.73 |
| EBITDA | N/A | N/A | N/A |
| Stock Option Compensation Expense | N/A | N/A | N/A |
| Price To Earnings Ratio | N/A | N/A | N/A |
| Price To Sales Ratio | N/A | N/A | N/A |
| Shares Outstanding | N/A | N/A | N/A |
| Market Capitalization | N/A | N/A | N/A |